Clinical Study

Oncg100- A Phase 2, Multicenter Open-Label, Non-Randomized Study Of Bavituximab Plus Pembrolizumab In Patients With Advanced Gastric Or Gastroesophageal Cancer Who Have Progressed On Or After At Least One Prior Standard Therapy

Posted Date: Feb 24, 2020

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to assess the safety and tolerability, and antitumor activity of bavituximab in combination with pembrolizumab in patients with advanced gastric/GEJ cancer.


To Be Eligible: Must Have Unresectable Metastatic Or Locally Advanced Gastric Or Gej Adenocarcinoma, At Least One Measurable Lesion, Ecog 0-1, No Surgery Or Rt With 4 Wks, Other Malignancy Within 3 Years, Hx Of Or Active Illness That May Impact Study


Gastroesophageal Cancer, Gastrointestinal, Gi

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.